ChemoCentrx has been working to develop a drug to combat auto-antibody-associated vasculitis (AAV), C3 glomerulopathy (C3G), and atypical hemolytic uremic syndrome (aHUS). Its name- Avacopan.
ChemoCentryx has always had a focus on inflammatory diseases, autoimmune diseases, and cancer. Their specialty is oral medication. Which, considering the myriad of other forms of treatment, is usually a favorite for patients. Of course you’ll take what you need, but it’s definitely a perk. The company presented its newest developments at two investor conferences in New York this June.
- Jefferies 2017 Global Healthcare Conference on June 8th
- JMP Securities 2017 Life Sciences Conference on June 21st
An audio webcast of the Jefferies conference presentation is available on ChemoCentryx.com.
In the meantime, development will continue for Avacopan. It is currently in Phase 3 development for AAV treatment, and all results so far have reassured researchers and the global community of its safety. Avacopan has officially been named an orphan-drug by the Food and Drug Administration. Likewise, the European Commission has designated it an “orphan medicinal product” for two forms of AAV and C3G, and the European Medicines Agency (EMA) has given Avacopan access to their PRIority Medicines (PRIME) initiative. The initiative is aimed at accelerating investment for studies focused on filling an unmet need within the medical community.
For aHUS, there definitely is a need, and hopefully this new drug will make an impact!
Read more about Avacopan on Nasdaq.com!
